Sindone, Andrew P and De Pasquale, Carmine and Amerena, John and Burdeniuk, Christine and Chan, Alicia and Coats, Andrew and Hare, David L and Macdonald, Peter and Sverdlov, Aaron and Atherton, John J (2022) Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia, 217 (4). pp.212-217. ISSN 0025-729X
Full text not available from this repository.Abstract
INTRODUCTION: This consensus statement of Australian clinicians provides new recommendations for the pharmacological management of heart failure based on studies reported since the publication of the 2018 Australian heart failure guidelines. MAIN RECOMMENDATIONS: blacksquare, square, filledUse of sodium-glucose cotransporter 2 (SGLT2) inhibitors to prevent hospitalisation for heart failure in type 2 diabetes mellitus can be extended to patients with multiple cardiovascular risk factors, albuminuric chronic kidney disease, or atherosclerotic cardiovascular disease. blacksquare, square, filledNew evidence supports the use of a mineralocorticoid receptor antagonist (finerenone) to prevent heart failure in type 2 diabetes mellitus associated with albuminuric chronic kidney disease. blacksquare, square, filledIn addition to renin angiotensin system inhibitors (angiotensin receptor neprilysin inhibitor preferred), beta blockers and mineralocorticoid receptor antagonists, an SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in all patients with heart failure with reduced left ventricular ejection fraction (LVEF </= 40%) (HFrEF). Lower quality evidence supports these therapies in patients with heart failure with mildly reduced LVEF (41-49%) (HFmrEF). blacksquare, square, filledA soluble guanylate cyclase stimulator (vericiguat), selective cardiac myosin activator (omecamtiv mecarbil) and, if iron deficient, intravenous iron (ferric carboxymaltose) provide additional benefits in persistent HFrEF. blacksquare, square, filledAn SGLT2 inhibitor (empagliflozin) should be considered in patients with heart failure with preserved LVEF (>/= 50%) (HFpEF). Key changes in management from this statement: This document broadens the scope of angiotensin receptor neprilysin inhibitor use in patients with HFrEF and HFmrEF. SGLT2 inhibitor use expands to become a cornerstone therapy in HFrEF, with increasing evidence to support its use in HFmrEF and HFpEF.
| Item Type: | Article |
|---|---|
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Repository Administrator |
| Date Deposited: | 01 Mar 2023 01:33 |
| Last Modified: | 01 Mar 2023 01:33 |
| URI: | https://eprints.victorchang.edu.au/id/eprint/1293 |
Actions (login required)
 |
View Item |